Rexis Biotech
About
Rexis makes proprietary ingredients for consumer-packaged goods that improve absorption and taste. Most plant-based ingredients have <10% absorption and lose 30% efficacy within 3 months. Rexis has signed multi-year contracts with 7 brands, projecting $14.7M in revenues with $24.6M in contracted distribution over 3 years.
AI Investment Summary
Rexis solves the bioavailability problem in supplements — most plant ingredients absorb at <10%. With $14.7M projected revenue and 7 brand contracts, this is one of the more traction-heavy Wefunder campaigns.
Structure
Direct Equity
Stage
Seed
Accreditation
Open to All
Liquidity
Illiquid
Geography
United States
Revenue
revenue generating
Funding Progress
45%Total Investors
800
Green Flags
- $14.7M projected revenues
- 7 brand contracts signed
- $24.6M in contracted distribution
- Solves real bioavailability problem
Risk Flags
- Revenue projections are forward-looking
- CPG ingredient market is competitive
- Dependent on brand partner growth
- Scale-up risk for manufacturing
Similar Deals in Biotech & Pharma
Oxeia Biopharma
Series A
First potential FDA-approved concussion treatment — Phase 2b clinical.
Min. Investment
$500
Funded
55%
Aarvik Therapeutics
Seed
Reengineering life-saving injections — $3M+ raised, top Wefunder campaign.
Min. Investment
$100
Minimum Investment
$100
Valuation
$12M
Lock-up Period
5 years (until exit)
Tags
LISTED
2026-01-15
ANNUAL REVENUE
$14.7M projected